siRNA targeting Gli-1 inhibited cell growth in ESCC cells. Gli-1 was expressed in 52 of 104 cancer specimens (50%). Gli-1 expression was associated with tumor depth (p ! 0.001), positive lymph node metastasis (p = 0.004) and a poor prognosis (p = 0.0047). Conclusion: Our results raise the possibility that the inhibition of the Hh pathway could be a novel target for esophageal cancer therapy.
Introduction
Esophageal carcinoma is the eighth most frequent cause of cancer death in the world [1] , and esophageal squamous cell carcinoma (ESCC) accounts for 90% of esophageal carcinomas in Asian countries. Although surgical techniques and perioperative management have progressed, the prognosis for patients with ESCC remains poor. Finding molecular therapeutic targets for ESCC treatment is one of the most promising avenues of research that might help to improve the survival of patients with this type of refractory cancer. Some of the genetic alterations associated with the development and progression of ESCC have been described [2] . However, few of these genes have been demonstrated to be associated with the biological or pathological features of ESCC. There-fore, there is a need to identify novel genes associated with the progression of ESCC.
Recent reports have demonstrated that the Sonic hedgehog (SHh) signaling pathway plays an important role in the development of various organs, including the neural tube, lung, gastrointestinal tract, pancreas, and the prostate [3] . SHh proteins act through the transmembrane proteins Patched (Ptch) and Smoothened (Smo), which regulate the transcriptional activity of three Gli zinc finger transcription factors [3, 4] . Normally, this pathway regulates cell growth and differentiation during embryonic tissue patterning as well as adult tissue homeostasis and may, in particular, be important for the maintenance of stem cell compartments in certain epithelia [3, 4] . Increased hedgehog signaling, e.g. in the skin, cerebellum, muscle, lung, digestive tract, pancreas and prostate, can lead to cancer [5] [6] [7] [8] [9] [10] . In addition, Hh signaling pathway activity is associated with tumor metastasis [10] .
In a previous report, we have demonstrated that the inhibition of the SHh signaling pathway by cyclopamine, a selective inhibitor of the Hh signaling pathway, inhibited the proliferation of a few ESCC cell lines [5] . However, there are few reports concerning the SHh signaling pathway status in human ESCC specimens [11] .
In this study, to clarify the possible involvement of the SHh signaling pathway in ESCC and to evaluate the clinical significance of SHh signaling in this disease, we examined the expression of SHh signaling pathway components in ESCC and analyzed the clinicopathological as well as biological features of the SHh signaling pathway in ESCC.
Materials and Methods

Cell Cultures
The human ESCC cell lines (KYSE series) [12] were established in our laboratory. KYSE cell lines were cultured in Ham/ RPMI supplemented with 2% fetal calf serum. The cells were grown at 37 ° C, 5% CO 2 in fully humidified air.
Patients and Surgical Specimens
A total of 104 ESCC patients who underwent surgery at the Kyoto University Hospital between 1990 and 2002 were examined. Twelve of these 104 patients were women, and 92 were men. The median age of the patients was 63 years (range: 50-84 years). Information on gender, age, disease stage and histopathological factors was retrieved from the medical records. All of the tumors were confirmed as ESCC by pathologists in the Department of Pathology of the Kyoto University Hospital. All of the patients were classified according to the sixth edition of the pathological tumor node metastasis (TNM) classification of 2002 [13] . Of the 104 patients, 27 (23.5%) had T1, 19 (26.2%) had T2, 45 (32.1%) had T3, and 13 (18.2%) had T4 disease. Written informed consent was obtained from the patients for surgery and to use resected samples for research. (The approval numbers of the International Review Board of the Kyoto University are 232 and G48.)
RT-PCR
Semiquantitative reverse transcription for SHh, Ptch, Smo Gli-1, Gli-2, and Gli-3 using total cellular RNA (5 g) was done for each sample using a first-strand cDNA synthesis kit (Amersham, Amersham, UK), and cDNA was subjected to PCR for 20, 25, 30, 35, 40 , and 45 cycles of amplification, respectively, using an Advantage cDNA PCR kit (Becton Dickinson Biosciences, Palo Alto, Calif., USA). Amplification was done at annealing temperatures of 57 (SHh and Gli-1) or 52 ° C (Ptch, Smo, and GAPDH) and an extension step at 72 ° C. The amplification products were separated by electrophoresis on 1.5% agarose gels and visualized by ethidium bromide staining. The oligonucleotides used as primer pairs (sense/anti-sense) were as described previously [14- SHh sense  5-GATGTCTGCTGCTAGTCCTCG-3  Anti-sense  5-CACCTCTGAGTCATCAGCCTG-3  Ptch sense  5-TCCCAAGCAAATGTACGAGCA-3  Anti-sense  5-TGAGTGGAGTTCTGTGCGACAC-3  Smo sense  5-CTGGTACGAGGACGTGGAGG-3  Anti-sense  5-AGGGTGAAGAGCGTGCAGAG-3  Gli-1 sense  5-CTCCCGAAGGACAGGTATGTAAC-3  Anti-sense  5-CCCTACTCTTTAGGCACTAGAGTTG-3  Gli-2 sense  5-CGAGAAACCCTACATCTGCAAGA-3  Anti-sense  5-GTGGACCGTTTTCACATGCTT-3  Gli-3 sense  5-AAACCCCAATCATGGACTCAAC-3  Anti-sense  5-TACGTGCTCCATCCATTTGGT-3  GAPDH sense 5-TGGTATCGTGGAAGGACTCATGAC-3 Anti-sense 5-ATGCCAGTGAGCTTCCCGTTCAGC-3 [5, 11] .
Proliferation Assay
Cyclopamine and tomatidine were purchased from Biomol Research Laboratories (Plymouth Meeting, Pa., USA). Cyclopamine was dissolved in ethanol and added in vitro at the concentrations indicated in the Results section. Tomatidine was added to control samples. To test for cyclopamine responsiveness, human ESCC cells were grown for 5 days in control medium containing tomatidine or experimental medium containing cyclopamine. We changed the medium every 2 days. Cell proliferation was assessed by a dye exclusion test every 2 days.
Cell Migration Assay
Cell motility was examined using a micropore chamber assay. Cells (5 ! 10 3 ) were seeded into the top chamber of a 24-well micropore polycarbonate membrane filter device with 8-m pores (Becton Dickinson Labware, Lincoln Park, N.J., USA), and the bottom chamber was filled with RPMI 1640 and Ham's F12 mixed medium containing 5% fetal bovine serum as a chemoattractant. Both chambers were supplemented with tomatidine (5 M ) in control medium or cyclopamine (5 M ) in experimental medium. After 22 h of incubation at 37 ° C, the membranes were fixed and stained with Diff-Quik reagent (International Reagents, Kobe, Japan), and all of the cells that had migrated through the membrane were counted under a light microscope. Each experiment was performed in triplicate wells and repeated three times. Before this experiment, we checked that there was no difference between the growth of the cells in the control medium and experimental medium during 22 h.
Cell Invasion Assay
The invasive capacity was examined using an invasion chamber assay. Cells (5 ! 10 3 ) were seeded into the upper chamber of a 24-well Matrigel-coated micropore membrane filter device with 8-m pores (Becton Dickinson Labware), and the bottom chamber was filled with RPMI 1640 and Ham's F12 mixed medium containing 5% fetal bovine serum as a chemoattractant. Both of the chambers were supplemented with tomatidine (5 M ) for the control medium or cyclopamine (5 M ) for the experimental medium. After 22 h of incubation at 37 ° C, the membranes were fixed and stained with Diff-Quik reagent. Then all of the cells that had migrated through the membrane were counted under a light microscope. Each experiment was performed in triplicate wells.
Immunocytochemical Staining KYSE890 cells were cultured with 5 M cyclopamine. Twentyfour hours later, the cultured cells were fixed with 4% paraformaldehyde at room temperature for 30 min. Endogenous peroxidase and nonspecific antibody reactivity were blocked with peroxidase-blocking reagent (Dako Cytomation, Glostrup, Denmark) at room temperature for 15 min. The cultured cells were then incubated for 1 h at room temperature with anti-human GLI-1 polyclonal antibody (C-18 Santa Cruz: diluted 1: 10). After rinsing in PBS, the cells were incubated with FITC-conjugated mouse antigoat immunoglobulin (Dako Cytomation) for 30 min at room temperature, and then mounted for microscopic examination.
Western Blot Analysis
Cells were lysed in a sample buffer (2% sodium dodecyl sulfate, 10% glycerol, and 50 m M Tris-HCl, pH 6.8) at room temperature. Cell lysates were sonicated and protein concentration was estimated by the Bradford method using BioRad protein assay reagent (BioRad Laboratories, Hercules, Calif., USA). After boiling for 3 min, cell lysates (20 g) were electrophoresed on 2-15% gradient polyacrylamide gel (Daiichi Pure Chemicals, Tokyo, Japan) and transferred to PVDF membranes (Immobilon, Millipore, Bedford, Mass., USA). Membranes were blocked with 2% skim milk (Difco, Detroit, Mich., USA) in 0.1% Tween-20 in TBS (20 m M Tris, 150 m M NaCl, pH 7.6) for 1 h at room temperature. Anti-human GLI-1 polyclonal antibody (C-18 Santa Cruz: diluted 1: 100) was used as the first antibody against the Gli-1-intracellular domain. The membrane was subsequently incubated at room temperature for 1 h with horseradish peroxidase-linked rabbit anti-goat IgG (EY Laboratories, San Mateo, Calif., USA; diluted 1: 1,000) The final detection of specific proteins was carried out using enhanced chemiluminescence reagents (Amersham Biosciences, Piscataway, N.J., USA) and visualized on X-ray film.
Small Interfering RNA Transfect Ion
The sequences used for siRNA targeting of Gli-1 (si Trio THF27A-344-C; B-Bridge International, Sunnyvale, Calif., USA) used in this study were a cocktail of three sequences ( table 2 ) . The nonspecific control siRNA (NSC) purchased from Dhamacon (Lafayette, Colo., USA) had the following sequences: sense, 5 -AUU GUA UGC GAU CGC AGA C UU-3 , and anti-sense, 5 -G UCU GCG AUC GCA UAC AAU UU-3 . KYSE170 cells were trypsinized and replated in 6-well dishes. After 24 h, at 20-50% confluency, cells were transfected with siRNA using oligofectamine reagent (Invitrogen, Carlsbad, Calif., USA) according to the manufacturer's instructions. The final concentration of siRNA was 80 n M . Cells were used for analysis 48 h after transfection.
THF27A-344-1 sense GGGAGGACCUCGAGAGA TT Anti-sense  UCUCUCUCGAGGUCCUCCC TT  THF27A-344-2 sense  GCGAAAACAUGUCAAGACA TT  Anti-sense  UUCUUGACAUGUUUUCGC TT  THF27A-344-3 sense GCAAAUAGGGCUUCACAUA TT Anti-sense UAUGUGAAGCCCUAUUUGC TT Table 2 . Sequences of siRNA targeting Gli-1
Immunohistochemistry
Resected esophageal specimens were fixed in 10% formaldehyde and then embedded in paraffin. Sections were cut and mounted on aminopropyltriethoxysilane-coated glass slides, and immunohistochemical staining was done using an LSAB+ System-HRP (Dako Cytomation). Unmasking of antigens was carried out by incubation in the target retrieval solution (Dako Cytomation) buffer at 100 ° C for 20 min in a microwave oven. The sections were then incubated overnight at 4 ° C with anti-human GLI-1 polyclonal antibody (C-18 Santa Cruz: diluted 1: 10). Thereafter, the sections were incubated with biotinylated link universal and then with streptavidin conjugated to horseradish peroxidase (Dako Cytomation) each for 30 min at room temperature. After rinsing in TBS thrice for 10 min each, they were incubated with 3,3 -diaminobenzidine solution (Dako Cytomation) for 1 min, counterstained with Mayer's hematoxylin, dehydrated, and then mounted for evaluation of immunohistochemical staining.
Evaluation of Immunohistochemical Staining
A section treated with blocking peptide (Santa Cruz) was used as a negative control for each case. Positive staining of the nucleus was evaluated in three areas of each section. The samples were divided into two groups (positive and negative) according to the percentage of Gli-1 cells with positive nuclear staining among the tumor cells, with tumors being classified as positive when 1 25% of the nuclei in the tumor were stained. All slides were independently evaluated by two investigators without prior knowledge of each patient's clinical information. When the opinions of the two evaluators (Y.M. and T.O.) were different, agreement was reached based on careful discussion. The reproducibility of the evaluations of each investigator was tested via a third assessment for all cases.
Statistical Analyses
Cumulative survival analysis was done using the Kaplan-Meier method and analyzed by the log-rank test. The correlation between Gli-1 expression and each clinicopathologic factor was evaluated by Fisher's exact test. Multivariate analysis was done using the Cox proportional hazard model. Each statistical analysis was done using StatView 4.5 (Abacus Concept, Berkley, Calif., USA). p ! 0.05 was considered to indicate statistical significance.
Results
Hedgehog Signaling Pathway Expression Components in ESCC Cell Lines
To examine the expression of SHh signaling pathway components (SHh, Ptch, Smo, Gli-1, Gli-2, and Gli-3) in ESCC, we performed semiquantitative RT-PCR in 34 KYSE cell lines. In 30 cycles, distinct bands of SHh and Smo were visualized in just 25 cell lines, but in 35 cycles, both genes were clearly detectable in all 34 cell lines. A clear band of Ptch was identifiable after running 40 cycles in all cell lines. We detected Gli-1 expression in 31 cell lines in 35 cycles; however, it was undetectable in KYSE70, KYSE770 and KYSE1440 cells even after 45 cycles. SHh, Ptch, and Smo expression was detected in all 34 cell lines, but 3 of 34 cell lines (9%) had undetectable levels of Gli-1 expression, whereas 31 of the 34 cell lines (91%; fig. 1 ,  table 3 ) expressed all of the tested SHh signaling pathway components. Gli-2 and Gli-3 were expressed in all 34 cell lines (data not shown). There are not any apparent morphologic or phenotypic differences in the 3 cell lines that lacked Gli-1 expression as compared to the other cell lines.
Growth Suppression by Cyclopamine in ESCC Cell Lines
The expression of the SHh signaling pathway components may affect the growth of ESCC cell lines. To investigate this possibility, we performed a cell growth assay using cyclopamine. At first, to determine the appropriate concentration of cyclopamine, we performed a cell growth assay using 2 KYSE cell lines (KYSE890 and KYSE70) treated with 0, 3, 5, and 10 M of cyclopamine. As shown in figure 2 a , we found that cyclopamine treatment reduced the growth of KYSE890, which expressed all the SHh signaling pathway components, in a dose-dependent manner, whereas cyclopamine did not affect the growth of KYSE70 which lacks Gli-1 expression ( fig. 2 b) . We then performed further examinations using 4 other cell lines at 5 M of cyclopamine. We found that cyclopamine treatment significantly reduced the growth of 2 KYSE cell lines (KYSE170 and KYSE180; fig. 2 c, d ) which expressed all the SHh signaling pathway components, whereas it did not affect the growth of 2 KYSE cell lines (KYSE770 and KYSE1440) lacking Gli-1 expression ( fig. 2 e, f) .
Suppression of Motility and Invasion of KYSE170 and KYSE70 Cells by Cyclopamine
The expression of the SHh signaling pathway components may affect the motility and invasion of ESCC cell lines. To examine the role of the SHh signaling pathway in the motility and the invasive capacity of the ESCC cell lines, we performed cell migration and cell invasion assays. We also performed growth assays for the KYSE170 and KYSE70 cells at 22 h and we confirmed that there was no difference in growth between the control and the treatment groups (data not shown). As shown in figure 3 , the migration assay indicated that motility was significantly suppressed by cyclopamine in KYSE170 (p = 0.001) but not in KYSE70 (p = 0.624). In addition, the cell invasion assay revealed that the invasive capacity of KYSE170 was slightly suppressed by cyclopamine, but that of KYSE70 was not affected (data not shown).
Immunocytochemistry and Western Blotting of Gli-1 in ESCC Cells
Immunocytochemistry using antibody against Gli-1 showed strong staining of the nucleus of KYSE890 as a control. KYSE890 cells treated for 24 h with cyclopamine lacked the nuclear staining ( fig. 4 a, b) , and the expression of Gli-1 in KYSE890 at protein level was inhibited by cyclopamine as shown by Western blot analysis ( fig. 4 c) .
Inhibition of Gli-1 Expression by SiRNA
Since the expression of Gli-1 is associated with the proliferation of ESCC cell lines, we next examined whether Gli-1 was necessary for maintaining the proliferation potential of the ESCC cell line. Forty-eight hours after transient transfection of siRNA targeting Gli-1 mRNA into KYSE170, the expression of Gli-1 at protein level was successfully inhibited as shown by Western blot analysis ( fig. 5 a) . The downregulation of Gli-1 expression occurred in parallel with the inhibition of cell growth ( fig. 5 b) . Furthermore, we examined the response of KYSE170 cells to cyclopamine following Gli-1 siRNA treatment. Cyclopamine did not inhibit the proliferation of the cells treated with siRNA whereas growth of the control cells was significantly inhibited ( fig. 5 c) .
Immunohistochemical Staining Patterns
The findings described above led us to speculate that upregulation of Gli-1 might be detected in the surgical specimens of ESCC. For the immunohistochemical study, we first examined the staining pattern of Gli-1 in the specimens. Analysis using the immunofluorescent staining revealed a nuclear staining pattern of Gli-1 in KYSE890 cells ( fig. 4 a, b) and, therefore, we focused on nuclear staining of the surgical specimens. Cytoplasmic staining was also observed in the tumors, but we classified the tumors only according to the percentage of cells positive for nuclear staining. A representative tumor with intense nuclear staining reflecting Gli-1 expression is shown in figure. 6 a, b. On the other hand, some specimens did not show nuclear staining ( fig. 6 c, d) . We scored the percentage of cells with positive nuclear staining among the tumor cells and the distribution of Gli-1 immunohistochemical expression among the 104 patients ( table 4 ) . For these specimens, the median percentage of nuclear staining was 25%. We classified the 52 tumors with staining of 1 25% of the nucleus as positive, whereas the 52 tumors with staining of ! 25% were classified as negative.
Correlation between Gli-1 Immunohistochemical Positivity and Clinicopathologic Findings
Among the 104 patients, positive Gli-1 expression was associated with the extent of the primary tumor (p ! 0.001) and lymph node metastasis (p = 0.004). However, it was not associated with gender, age, histological grade or metastasis factor ( table 5 ) .
Gli-1 Immunohistochemical Positivity and Patient Prognosis
Overall, the cumulative rate of survival of the patients with Gli-1-positive tumors was significantly lower than that of the patients with Gli-1-negative tumors (p = 0.0047; fig. 6 e) . On the other hand, Cox's multivariate analysis revealed that the lymph node metastasis (p = 0.003) was an independent prognostic factor ( table 6 ), but Gli-1 status was not (p = 0.356). 
Discussion
In the present study, we examined the biological and clinical significance of the Hedgehog signaling pathway in ESCC. We found that the expression of SHh, Ptch, Smo, and Gli-1 was mostly maintained in ESCC cell lines. However, in a few ESCC cell lines, the expression of Gli-1 was not detected. This result suggests that the Hedgehog signaling pathway may generally be activated in ESCC.
The growth suppression by cyclopamine in several cancer cell lines has already been reported [5, 11, 17] . We confirmed this in a large number of ESCC cell lines. Our study also demonstrated that cell migration of ESCC cells was inhibited by cyclopamine. These data suggest that the activation of the SHh signaling pathway may be associated with tumor growth and migration of ESCC cells, and the inhibition of the SHh signaling pathway may be useful for preventing them.
To examine the intracellular effect of cyclopamine in ESCC cells, we performed immunocytochemical staining and Western blot analysis of Gli-1. The expression of Gli-1 at protein level was inhibited by cyclopamine. Furthermore, the expression of Gli-1 in the nucleus was reduced by cyclopamine in KYSE890. These results suggested that cyclopamine may inhibit the cell proliferation and migration by suppressing the expression of Gli-1 in the nucleus, and that the Gli-1 expression in the nucleus is important for the functioning of the Hedgehog signaling pathway. Our study also demonstrated that the inhibition of Gli-1 expression using transient transfection of siRNA resulted in a marked inhibition of cell growth. A recent study also found that the ESCC cells showing Gli-1 overexpression resisted growth suppression by cyclopamine [11] . Thus, in ESCC, Gli-1 plays a crucial role when the Hedgehog signaling pathway is acting. The inhibition of Gli-1 expression may be a main target of the therapy for ESCC in which the Hh signaling pathway is involved. However, there were a few ESCC cell lines that lacked the expression of Gli-1, and their growth was not suppressed by cyclopamine. It has been shown that Gli-1 functions only as a transactivator [18] . Furthermore, Kogerman et al. [19] reported that the nuclear entry of Gli-1 was important for the SHh signaling pathway to work. Thus, the block of the nuclear entry of Gli-1 inhibited transcriptional activation of target genes, and Mao et al. [20] also reported that the elevated Gli-1 protein levels in the nucleus enhanced the transcriptional activity of Gli-1. Moreover, Kubo et al. [17] also reported that there was an association of the nuclear staining ratio of Gli-1 with the expression of estrogen receptor and with histologic type in breast cancer. Based on these observations and our results that cyclopamine inhibited the nuclear expression of Gli-1 in ESCC cells, we deduced that the Gli-1 expression in the nucleus was important for the SHh signaling pathway to work in ESCC patients. Then we analyzed the correlation between the nuclear staining of Gli-1 and conventional histopathologic findings. Our data suggested that the nuclear staining rate of Gli-1 is associated with the extent of the primary tumor, lymph node metastasis, and the prognosis of ESCC patients. Karhadkar et al. [10] reported that the hedgehog signaling pathway activity promotes tumor metastasis in prostate cancer, and our data were compatible with their report.
Gli-1 is a strong activator of downstream target genes and it is itself a transcriptional target of the Hh signaling pathway. An activating mutation of Smo or a suppressing mutation of Ptch in turn activates the Hh pathway in a constitutive and ligand-independent manner. These mutations have been identified in tumors of the brain, skin, and muscle [8, 21] . Further, recent studies have shown cell autonomous, ligand-dependent activation of the Hh signaling pathway in small cell lung cancer and pancreatic cancer [6, 7] . However, the mechanism which regulates Gli-1 activation in ESCC remains unclear. At present, the hedgehog signaling target genes found by microarray analysis include genes encoding molecules involved in the cell cycle [22] , cell adhesion [23] , signal transduction [22] , apoptosis [22, 23] , nerve formation [23] , angiogenesis [24] , and transcriptional regulation [23] , as well as Wnt signaling antagonists [23] , protease inhibitors, and a metal-binding protein [25] . However, the actual role and the regulation of the hedgehog signaling pathway in normal tissues and cancer remain unclear [26] .
In conclusion, we have demonstrated that Gli-1 expression was associated with the depth of invasion, the status of the lymph node metastasis, and the prognosis of ESCC. We have clarified that the hedgehog signaling pathway modulated cell growth and the migration of ESCC cells in vitro. These findings strongly suggest that the hedgehog signaling pathway plays an important role in ESCC progression and would provide a novel molecular target for the treatment of ESCC.
